Frederick Kahn, MD
Psychosomatic Medicine · Paramus, NJNPI 1316160039
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Orexo US, Inc. at 53.4% of the total. Reporting peaked in 2019 at $1,602 and has fallen 67.6% since, to $519 in 2025.
Across 43 payments — averaging $56.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Orexo US, Inc.$1K
- Braeburn Inc.$473
- Kerecis Limited$218
- Otsuka America Pharmaceutical, Inc.$166
- Johnson & Johnson$109
- Vanda Pharmaceuticals Inc.$35
- plus $126 from 8 others
What the payments were for
- Consulting fees$1,25052%
- Travel & lodging$191%
- Food & beverage$1,15348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Orexo US, Inc. | 4 | $1,294 |
| Braeburn Inc. | 22 | $473 |
| Kerecis Limited | 1 | $218 |
| Otsuka America Pharmaceutical, Inc. | 4 | $166 |
| Johnson & Johnson | 1 | $109 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| Indivior Inc. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $15 |
| AbbVie | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zubsolv$1,250
- Kerecis Omega3 Marigen$874
- BRIXADI$246
- Kerecis Omega3 SurgiClose$218
- REXULTI$115
- SPRAVATO$109
How this compares
Too few psychosomatic medicine providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $12,300 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,084 |
| Lurasidone Hcl | 12 | $3,487 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 112 | $3,451 |
| Buprenorphine Hcl | 115 | $3,368 |
| Fentanyl | 20 | $2,001 |
| Methylphenidate Hcl | 30 | $1,724 |
| Alprazolam | 223 | $1,392 |
| Bupropion XlBupropion Hcl | 34 | $1,340 |
| Clonazepam | 110 | $1,136 |
| Olanzapine | 13 | $1,040 |
| Divalproex Sodium | 32 | $921 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 20 | $553 |
| Oxycodone Hcl | 35 | $499 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $14 | $4,08411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychosomatic medicine providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other psychosomatic medicine in Paramus
- Ashwini NeelgundMatawan$8K
- Pamela WilliamsPassaic$7K
- Ayman RamzySkillman$974
- Jan ChrobokGillette$744
- Adriana PhanHackensack$455
- Thomas CampoCherry Hill$116
- Annamaria NucciCedar Grove$110
- Justin CapoteMontclair$101
- Nina SugarRidgewood$49
- Lawrence EisensteinRed Bank$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.